Phase II Study of Parsaclisib Add-on Therapy in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results

Source: Independent Conference Highlights of the 2022 ASH Annual Meeting*
Download Slideset
December 10-13, 2022; New Orleans, Louisiana
Adding the PI3K inhibitor parsaclisib to ruxolitinib reduced spleen volume and improved symptom burden in patients with myelofibrosis and an inadequate response to ruxolitinib.
Format: Microsoft PowerPoint (.ppt)
File Size: 290 KB
Released: December 14, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie
AstraZeneca
Amgen
Epizyme
GSK
Incyte Corporation
Jazz Pharmaceuticals
Karyopharm Therapeutics Inc.
Novartis Pharmaceuticals Corporation
Sanofi
Seagen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings